Follow the Medicenna Therapeutics Corp. share price and the full management transaction log of the company, a listed equity based in Canada. Shares are quoted on CA CA, under the supervision of SEDI. Market capitalisation: €24.3m. The latest transaction was disclosed on 2 June 2026 (15 - Acquisition or disposition under a prospectus). Among the most active insiders: Merchant, Fahar. The full history is free.
14
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
39Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
50,000 shares@ CA$0.05100.0% of flowCommon SharesTSXSEDI:4726819
Canonical exit: 26 Aug 2026 (T+90)
14 of 14 declarations
About Medicenna Therapeutics Corp.
Medicenna Therapeutics Corp. is a biopharmaceutical company focused on developing cytokine-based therapies for cancer treatment. It is listed on the Toronto Stock Exchange under the symbol MDNA.